Comparison of 250 ml Versus 500 ml of Fluid Challenge (KOBIAS)

Comparison of 250 ml Versus 500 ml of Fluid Challenge on Oxygen Consumption in Critical Care Patients: an Open Label Multicentre Prospective Study

The objective of fluid challenge is to increase oxygen delivery (DO2) in order to improve/restore tissue oxygen consumption (VO2). However the fluid challenge volume to administer stills in debate, some studies recommend to administer 250 mL. Previous studies suggested that 500 mL of fluid challenge administration may improve cardiac output and oxygen delivery. The relation between the amount of fluid expansion and oxygen delivery and oxygen consumption was not yet been studied in a randomized study in critical care patients. This is the purpose of this study.

Study Overview

Status

Active, not recruiting

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

24

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Amiens, France
        • CHU Amiens Picardie

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patient for whom the physician in charge decided to infuse fluid challenge because of signs of acute circulatory failure (systolic arterial blood pressure < 90mmHg, and/or mean arterial blood pressure< 65 mmHg, and/or the need of vasopressive amine infusion, and/or skin mottling, and/or diuresis <0.5 mL/kg/h for more than 2 hours, and/or arterial lactate level>2mmol/L.
  • Echogenic patient
  • Patient with a Stroke Volume (SV) variation with passive leg raising (PLR) more than 10%.
  • Patient with regular sinus rhythm.
  • Patient who received protocol information.

Exclusion Criteria:

  • Age Under 18-year-old.
  • Pregnancy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: 250 mL of fluid challenge
After randomisation, patient will receive 250 ml or 500 ml of fluid challenge. VO2 will be assessed before fluid challenge, immediately, 30 minutes and 60 minutes after fluid challenge.
Experimental: 500 mL of fluid challenge
After randomisation, patient will receive 250 ml or 500 ml of fluid challenge. VO2 will be assessed before fluid challenge, immediately, 30 minutes and 60 minutes after fluid challenge.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
VO2 after fluid challenge
Time Frame: 30 minutes after fluid challenge.
Tissue oxygen consumption (VO2) after fluid challenge
30 minutes after fluid challenge.
VO2 after fluid challenge
Time Frame: 60 minutes after fluid challenge.
Tissue oxygen consumption (VO2) after fluid challenge
60 minutes after fluid challenge.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of arterial lactate concentration from baseline
Time Frame: 30 minutes after fluid challenge.
Baseline is the measurement of arterial lactate concentration immediately after fluid challenge
30 minutes after fluid challenge.
Change of arterial lactate concentration from baseline
Time Frame: 60 minutes after fluid challenge.
Baseline is the measurement of arterial lactate concentration immediately after fluid challenge
60 minutes after fluid challenge.
Respiratory variation of stroke volume
Time Frame: Immediately, 30 and 60 minutes after fluid challenge.
Respiratory variation of stroke volume after fluid challenge.
Immediately, 30 and 60 minutes after fluid challenge.
PaO2/FiO2
Time Frame: Immediately, 30 and 60 minutes after fluid challenge.
PaO2/FiO2 ratio (ratio of arterial oxygen partial pressure to fractional inspired oxygen) after fluid challenge
Immediately, 30 and 60 minutes after fluid challenge.
Respiratory variation of the pulse pressure
Time Frame: 30 and 60 minutes after fluid challenge.
Respiratory variation of the pulse pressure
30 and 60 minutes after fluid challenge.
Stroke volume variation with passive leg raising (PLV)
Time Frame: 30 and 60 minutes after fluid challenge.
Stroke volume variation with passive leg raising (PLV)
30 and 60 minutes after fluid challenge.
Systolic heart function (LVEF)
Time Frame: Immediately, 30 and 60 minutes after fluid challenge.
Systolic heart function (LVEF)
Immediately, 30 and 60 minutes after fluid challenge.
Diastolic heart function
Time Frame: Immediately, 30 and 60 minutes after fluid challenge.
Diastolic heart function (E, A, E', A', S' waves)
Immediately, 30 and 60 minutes after fluid challenge.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Osama Abou-Arab, Dr, CHU Amiens

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2019

Primary Completion (Actual)

May 24, 2021

Study Completion (Anticipated)

August 1, 2023

Study Registration Dates

First Submitted

March 7, 2019

First Submitted That Met QC Criteria

March 12, 2019

First Posted (Actual)

March 14, 2019

Study Record Updates

Last Update Posted (Actual)

May 17, 2023

Last Update Submitted That Met QC Criteria

May 16, 2023

Last Verified

May 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • PI2018_843_0034

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Oxygen Consumption

Clinical Trials on Fluid challenge

3
Subscribe